AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29241713 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heating (hot packs) with insulation maintained for an additional 30 minutes
Number of subjects: 21
Study 27528062 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved automated office BP at baseline
Number of subjects: 6183
Study 27528062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure at ≥80 mm Hg
Number of subjects: 6183
Study 25483635 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagreb regimen (2-1-1)
Number of subjects: 825
Study 25483635 — intervention group
Group type: COMPARATOR
Intervention: Essen regimen
Number of subjects: 825
Study 22929263 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular TRAM flap with single-nerve anastomosis
Number of subjects: 60
Study 22929263 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular TRAM flap with double-nerve anastomosis
Number of subjects: 60
Study 22929263 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular TRAM flap with no nerve dissection
Number of subjects: 60
Study 22929263 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study 22929263 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical techniques (including microvascular TRAM flap)
Number of subjects: 60
Study 20084540 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative lesions without atypia
Number of subjects: 1239
Study 20084540 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical hyperplasia
Number of subjects: 1239
Study 20084540 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple foci of columnar cell hyperplasia and complex fibroadenoma without atypia
Number of subjects: 1239
Study 20084540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing adenosis, radial scar, and papilloma
Number of subjects: 1239
Study 18701886 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine dose
Number of subjects: 10
Study 18701886 — intervention group
Group type: EXPERIMENTAL
Intervention: Total buprenorphine meconium concentrations and buprenorphine/norbuprenorphine ratios
Number of subjects: 10
Study 18701886 — intervention group
Group type: EXPERIMENTAL
Intervention: Free buprenorphine concentration and percentage free buprenorphine
Number of subjects: 10
Study 18701886 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice‐weekly urine tests for opiates, cocaine, and benzodiazepines
Number of subjects: 10
Study 18701886 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and metabolite concentrations in meconium
Number of subjects: 10
Study 15795438 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 689
Study 12846271 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (n = 151) received a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Number of subjects: 331
Study 12846271 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT group (n = 180) received 93 mg calcium alone or in combination with vitamin D3 (100-300 IU/day)
Number of subjects: 331
Study 10975887 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental anesthesia
Number of subjects: 12
Study 8970354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg
Number of subjects: 72
Study 8970354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8245327 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 2546
Study 8245327 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravenous metoprolol
Number of subjects: 2546
Study 8245327 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol angiography 18 to 48 hours after rt-PA
Number of subjects: 2546
Study 8245327 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival to 21 days
Number of subjects: 2546
Study 3915317 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 140
Study 3915317 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 140
Study 29439773 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing gel with 5% potassium nitrate and 5% glutaraldehyde
Number of subjects: 42
Study 29439773 — intervention group
Group type: COMPARATOR
Intervention: Placebo control gel
Number of subjects: 42
Study 27368057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 31
Study 27368057 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Continuous Training (MVCT)
Number of subjects: 31
Study 27368057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and MVCT
Number of subjects: 31
Study 24100412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS (+sham tDCS)
Number of subjects: 11
Study 24100412 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (+sham rTMS)
Number of subjects: 11
Study 24100412 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (sham rTMS+sham tDCS)
Number of subjects: 11
Study 21339541 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA) 3 x 6 g/d for 2 weeks
Number of subjects: 34
Study 21339541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LOLA)
Number of subjects: 34
Study 21339541 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA)
Number of subjects: 34
Study 21339541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 19108985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 1218
Study 19108985 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 1218
Study 19108985 — intervention group
Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 1218
Study 19108985 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical model
Number of subjects: 1218
Study 17898990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3356
Study 17898990 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3356
Study 17898990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3356
Study 17898990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3356
Study 15557360 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient partnership intervention (n = 107) received drug safety information and their medication list
Number of subjects: 209
Study 15557360 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102) received drug safety information only
Number of subjects: 209
Study 15557360 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient partnership intervention (n = 107)
Number of subjects: 209
Study 15557360 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 209
Study 15557360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse respondents
Number of subjects: 209
Study 11567990 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF) alone for 4 days at 10 microg/kg per day (arm A)
Number of subjects: 47
Study 11567990 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (5 g/m(2)) and G-CSF at 10 microg/kg per day until hematologic recovery (arm B)
Number of subjects: 47
Study 11567990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 47
Study 9633797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1292
Study 9633797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1292
Study 9633797 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1292
Study 9633797 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1292
Study 9633797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1292
Study 9633797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1292
Study 9633797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study 7880511 — intervention group
Group type: COMPARATOR
Intervention: Droperidol-fentanyl
Number of subjects: 20
Study 7880511 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-fentanyl
Number of subjects: 20
Study 3046772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100, 150 and 200 micrograms/kg
Number of subjects: 234
Study 3046772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 234
Study 3046772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 234
Study 3046772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 31128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment with trough concentrations greater than 23.1 mg/L at week 2
Number of subjects: 122
Study 31128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment with trough concentrations greater than 10.0 mg/L at week 6
Number of subjects: 122
Study 31128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab maintenance therapy with trough concentrations greater than 10.6 mg/L
Number of subjects: 122
Study 31128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fecal concentrations of calprotectin during therapy
Number of subjects: 122
Study 31128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent increase in fecal concentration of calprotectin despite dose escalation
Number of subjects: 122
Study 31128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with antibodies to infliximab
Number of subjects: 122
Study 29886103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/12h
Number of subjects: 80
Study 29886103 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 80
Study 28586262 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous diahemofiltration (CVVDH)
Number of subjects: 245
Study 28586262 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic peritoneal lavage and drainage (LPLD)
Number of subjects: 245
Study 28586262 — intervention group
Group type: EXPERIMENTAL
Intervention: LPLD + CVVDH
Number of subjects: 245
Study 28586262 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment
Number of subjects: 245
Study 24299075 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit self-esteem measures
Number of subjects: 1008
Study 24299075 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit self-esteem measures
Number of subjects: 1008
Study 24299075 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1008
Study 24299075 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit prime
Number of subjects: 1008
Study 24299075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime meant to activate self-competence related implicit attitudes
Number of subjects: 1008
Study 23262750 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25(OH)D
Number of subjects: 1211
Study 23262750 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 1,25(OH)2D
Number of subjects: 1211
Study 23262750 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR BsmI polymorphism
Number of subjects: 1211
Study 23262750 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR FokI polymorphism
Number of subjects: 1211
Study 20932651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with concurrent temozolomide (TMZ) chemotherapy, 60 Gy total dose, escalating from 3 Gy/fraction to 6 Gy/fraction, concurrent TMZ at 75 mg/m²/d for 28 days, adjuvant TMZ at 150-200 mg/m²/d for 5 days every 28 days.
Number of subjects: 16
Study 18094325 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 130
Study 18094325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 21251026 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reablation (ERe+) at 28.1 ± 2.7 days postablation
Number of subjects: 375
Study 21251026 — intervention group
Group type: COMPARATOR
Intervention: Nonearly reablation (ERe-) at 98.2 ± 5.2 days postablation
Number of subjects: 375
Study 16196417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.5 g/d for the first 4 months of lactation)
Number of subjects: 122
Study 16196417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 122
Study 16196417 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 122
Study 12269727 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 54
Study 12269727 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional perceptual-motor training
Number of subjects: 54
Study 12269727 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 54
Study 9542208 — intervention group
Group type: EXPERIMENTAL
Intervention: Colony-stimulating factors (G-CSF and GM-CSF) as adjunctive care
Number of subjects: 0
Study 9542208 — intervention group
Group type: COMPARATOR
Intervention: Control (no colony-stimulating factors)
Number of subjects: 0
Study 7651658 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 10 mg intravenously
Number of subjects: 28
Study 7651658 — intervention group
Group type: COMPARATOR
Intervention: meperidine 50 mg intravenously
Number of subjects: 28
Study 2682775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1: Provision of information about the imager and nature of the examination
Number of subjects: 50
Study 2682775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2: Information and counseling
Number of subjects: 50
Study 2682775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 3: Information and a 12-minute relaxation exercise
Number of subjects: 50
Study 326593 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate and bendrofluazide (10 mg timolol and 2-5 mg bendrofluazide, increased as needed)
Number of subjects: 12
Study 326593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29497287 — intervention group
Group type: EXPERIMENTAL
Intervention: NEM 500 mg
Number of subjects: 60
Study 29497287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27143321 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 4250
Study 27143321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4250
Study 24884770 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 346
Study 24884770 — intervention group
Group type: COMPARATOR
Intervention: Patch repair
Number of subjects: 346
Study 22858919 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (10, 50, 100, or 200 µM) dissolved in iopromide (contrast medium)
Number of subjects: 24
Study 22858919 — intervention group
Group type: COMPARATOR
Intervention: Control (iopromide without paclitaxel)
Number of subjects: 24
Study 21207920 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% calcium sodium phosphosilicate (NovaMin) dentifrice
Number of subjects: 120
Study 21207920 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride gel
Number of subjects: 120
Study 21207920 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 120
Study 18494967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone followed by P (8% carbamide peroxide solution)
Number of subjects: 60
Study 18494967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone concurrently with P (8% carbamide peroxide solution)
Number of subjects: 60
Study 18494967 — intervention group
Group type: COMPARATOR
Intervention: P alone (8% carbamide peroxide solution)
Number of subjects: 60
Study 18494967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone followed by P/TM (50:50 blend)
Number of subjects: 60
Study 18494967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone concurrently with P/TM (50:50 blend)
Number of subjects: 60
Study 18494967 — intervention group
Group type: COMPARATOR
Intervention: P/TM (50:50 blend) alone
Number of subjects: 60
Study 16435615 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of 0.75% ropivacaine + 25 microg of fentanyl
Number of subjects: 64
Study 16435615 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of 1% ropivacaine + 25 microg of fentanyl
Number of subjects: 64
Study 14559423 — intervention group
Group type: EXPERIMENTAL
Intervention: New table for microscopes
Number of subjects: 10
Study 14559423 — intervention group
Group type: COMPARATOR
Intervention: Old non-adjustable laboratory table
Number of subjects: 10
Study 10099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with MOPP/ABVD
Number of subjects: 24
Study 10099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with ABVD
Number of subjects: 24
Study 10099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with MOPP/ABVD or ABVD
Number of subjects: 24
Study 8735734 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical castration (total abdominal hysterectomy and bilateral salpingo‐oophorectomy)
Number of subjects: 27
Study 2015545 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) plus doxorubicin as adjuvant chemotherapy
Number of subjects: 125
Study 2015545 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 125
Study 6779618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg buccally
Number of subjects: 10
Study 6779618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31557380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day)
Number of subjects: 94
Study 31557380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 29519921 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg prednisone for 7 days
Number of subjects: 310
Study 29519921 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 310
Study 26346638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg/day
Number of subjects: 773
Study 26346638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773
Study 26346638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 and 70 mg/day
Number of subjects: 773
Study 26346638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 773
Study 24940656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ambulatory multidisciplinary rehabilitation
Number of subjects: 106
Study 24940656 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 106
Study 21176916 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet use (after legislation)
Number of subjects: 1684
Study 21176916 — intervention group
Group type: COMPARATOR
Intervention: Helmet use (before legislation)
Number of subjects: 1684
Study 21176916 — intervention group
Group type: EXPERIMENTAL
Intervention: Head injury
Number of subjects: 1684
Study 21176916 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal injury
Number of subjects: 1684
Study 20816122 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Candesartan
Number of subjects: 2049
Study 20816122 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2049
Study 17627903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastricture steroid injection (triamcinolone, 40 mg total dose)
Number of subjects: 13
Study 17627903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13
Study 16210155 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral foot blockade
Number of subjects: 51
Study 16210155 — intervention group
Group type: COMPARATOR
Intervention: Popliteal sciatic nerve block
Number of subjects: 51
Study 12389594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogens (50 microg 17 beta‐Estradiol/24 hr)
Number of subjects: 17
Study 12389594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12389594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogens with progestagens (10 mg daily for last 2 weeks)
Number of subjects: 17
Study 12389594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogens
Number of subjects: 17
Study 12394541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (55% water content)
Number of subjects: 56
Study 12394541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (38% water content)
Number of subjects: 56
Study 12394541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (Dk value of 90)
Number of subjects: 56
Study 12394541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (Dk value of 52)
Number of subjects: 56
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of type I muscle fibres and relative fibre area of type I
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary density (number of capillaries/muscle fibre)
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion distance (fibre area supplied by one capillary)
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of LPL and citrate synthase
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity of LPL
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/C-peptide ratio
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle fibre distribution variables
Number of subjects: 24
Study 9649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/C-peptide ratio (excluding muscle morphological variables)
Number of subjects: 24